IZOZF - Izotropic's Technical & Scientific Team Members Advocate for Commercialization of Breast CT Technology
(TheNewswire)
VANCOUVER, BC – TheNewswire - February 23,2023 – Izotropic Corporation (“ Izotropic ” orthe “ Company ”) (CSE: IZO ) (OTC: IZOZF )(FSE: 1R3 ), a medical device company commercializing IzoView, adedicated breast CT (computed tomography) imaging platform, for themore accurate detection and diagnosis of breast cancers, releasesstatements from select key members of its technicaland scientific teams and clinical capabilities of breast CT technology for thevery first time.
Dr. John M. Boone, Ph.D., is the founder of breast CTtechnology at UC Davis Medical Center, from where Izotropic licensedthe exclusive global technology rights to develop IzoView. Beginningwith a feasibility grant from the National Institutes of Health andapproximately $20 million USD in subsequent grant funding, foursuccessive breast CT research scanners were built and tested inclinical trials at The Boone Lab at UC Davis:
“We’ve done extensive studies onmammo[graphy], tomosynthesis, and breast CT… As we looked at thedata, it was clear that when you have contrast-enhanced breast CT, itcan virtually replace all other diagnostic examinations, includingmammo[graphy], tomo[synthesis], ultrasound, and even MR (MagneticResonance Imaging).” – Dr. John M. Boone
Dr. Shadi Shakeri, MD, FSBI, a fellowship-trainedradiologist, specializes in breast imaging, including digitalmammography, tomosynthesis, breast computed tomography, ultrasound,and magnetic resonance imaging. Dr. Shakeri has been in charge of theclinical aspects of breast CT clinical trials since 2017 at UC Davis.Her work has included clinical study design, recruiting, speaking topatients, and viewing and evaluating breast CT images, making her aunique authority on the capabilities and validity of breast CTtechnology:
“When we started using contrastwith the breast CT, the data that we saw, the images that we saw justblew you out of the water… there was just no comparison at all tomammography… I have seen, actually, cancers that are centimeters insize, so walnut-sized cancers that you absolutely have no idea existsin that breast when you look at it with either a traditional mammogramor tomosynthesis images. You take that same patient with that samewalnut-sized cancer, and you do a breast CT with contrast, and itlights up like a lightbulb that you can see from across the room, andthere is no doubt in anyone's mind that that is something that needsto be pursued, biopsied so that the patient can move on and get hertreatment." – Dr. Shadi Shakeri.
Dr. Craig Abbey, Ph.D., is a professional Researcher at the University of California, Santa Barbara,where his interests include modeling human observer strategies forperforming visual tasks in the presence of image noise and otherdegradations and assessment of medical imaging devices and imageprocessing in terms of performance in diagnostic and quantitativetasks. As a leader in his field, Dr. Abbey has served as a ScientificReviewer for the FDA, where he sat on independent review panels toevaluate reader studies proposed by companies seeking FDA approval ofmedical imaging devices. Notably, Dr. Abbey sat on the independentreview panel for the approval of Hologic's Digital BreastTomosynthesis and U-System's Automated Breast Ultrasound System(ABUS).
Dr. Abbey has been working closely with Izotropic onthe design of its forthcoming clinical study for USA marketauthorization as a diagnostic device:
“Medical imaging devices gothrough a special process at the FDA… the imaging device is only asgood as it helps the radiologist make an accurate decision, and sowhat you have to demonstrate in order to get through the FDA is thatyour imaging device will lead to greater diagnostic accuracy inradiologists… I have great hopes for the breast CT device, and Ibelieve it is capitalizing on something that will be very useful andvery beneficial to the women who undergo it. But the beauty of thesestudies is that it really doesn't matter what my hopes and dreams are.The study is designed to demonstrate it, or not." – Dr. CraigAbbey.
to see the full statements from Dr. Boone, Dr. Shakeri,Dr. Abbey, and more.
ON BEHALF OF THE BOARD
Investor Relations:
Email: info@izocorp.com
Toll Free: 1-833-IZOCORP ext.1
Media Inquiries:
Ms. Jaclyn Thast
Email: jaclyn@izocorp.com
Toll Free: 1-833-IZOCORP ext.3
About Izotropic Corporation
Izotropic Corporation is the only publicly tradedcompany commercializing a dedicated breast CT imaging platform,IzoView, for the more accurate detection and diagnosis of breastcancers. To expedite patient and provider access to IzoView,Izotropic's initial clinical study intends to demonstrate the superiorperformance of diagnostic breast CT imaging over diagnosticmammography procedures. In follow-on clinical studies, Izotropicintends to validate platform applications, including breast screeningin radiology, treatment planning and monitoring in surgical oncology,and breast reconstruction and implant monitoring in plastic andreconstructive surgery.
More information about Izotropic Corporation can befound on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
Forward-Looking Statements
This document may contain statements that are"Forward-Looking Statements," which are based upon thecurrent estimates, assumptions, projections, and expectations of theCompany's management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible, to identify suchinformation and statements by using words such as"anticipate," "believe," "envision,""estimate," "expect," "intend,""may," "plan," "predict,""project," "target," "potential,""will," "would," "could,""should," "continue," "contemplate" andother similar expressions and derivations thereof in connection withany discussion of future events, trends or prospects or futureoperating or financial performance, although not all forward-lookingstatements contain these identifying words.
These statements are not guarantees of performance andinvolve risks, including those related to capital requirements anduncertainties that are difficult to control or predict, and as such,they may cause future results of the Company's activity to differsignificantly from the content and implications of such statements.Forward-Looking Statements are pertinent only as of the date on whichthey are made, and the Company undertakes no obligation to update orrevise any Forward-Looking Statements to reflect new information or the occurrence of future events orcircumstances unless otherwise required to do so by law. Neither theCompany nor its shareholders, officers, and consultants shall beliable for any action and the results of any action taken by anyperson based on the information contained herein, including, withoutlimitation, the purchase or sale of Company securities. Nothing inthis document should be deemed to be medical or other advice of anykind. All images are for illustrative purposes only. IzoView is notyet approved for sale.
Copyright (c) 2023 TheNewswire - All rights reserved.